Lung Cancer Online

Search Lung Cancer Online

Print This PageEmail This Page

Maintenance therapy in NSCLC

More research is underway but the use of maintenance therapies is showing promise in NSCLC. The National Cancer Institute defines maintenance therapy as, "Treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy. It may include treatment with drugs, vaccines, or antibodies that kill cancer cells and it may be given for a long time."

Three drugs are used in NSCLC: Tarceva and Alimta have been approved by the FDA for maintenance and Avastin is being studied.  Maintenance may be continuation, meaning the patient stays on a drug they have already been taking or switch, meaning the patient changes to a new drug.  


Learn about NSCLC and maintenance therapies

Maintenance therapies (Lung Cancer Alliance)

New Approaches to Maintenance Therapy (InforMEDical) Three leading lung cancer specialists discuss maintenance therapy:

Reviews of the literature as of 2011

Novello et al. 2011. Maintenance therapy in NSCLC: Why? To whom? Which agent? Journal of Experimental and Clinical Cancer Research 30:50.

Coate and Shepherd. 2011. Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Advances in Medical Oncology 3(3):139-57.

Maintenance Therapy in Advanced Non-Small Cell Lung Cancer: Before We Accept This Treatment Paradigm, Let's Critically Evaluate and Interpret the Data (OncLive)

2012 summary of results of the Paramount trial

ASCO: Alimta extends survival in NSCLC (Med Page Today)